Document Report Card
Basic Information
ID: ALA2010643
Journal: Bioorg Med Chem Lett
Title: Characterization of TAE684 as a potent LRRK2 kinase inhibitor.
Authors: Zhang J, Deng X, Choi HG, Alessi DR, Gray NS.
Abstract: Leucine-rich repeat kinase 2 (LRRK2) is linked to Parkinson's disease and may represent an attractive therapeutic target. Here we report a 2,4-dianilino-5-chloro-pyrimidine, TAE684, a previously reported inhibitor of anaplastic lymphoma kinase (ALK), is also a potent inhibitor of LRRK2 kinase activity (IC(50) of 7.8nM against wild-type LRRK2, 6.1nM against the G2019S mutant). TAE684 substantially inhibits Ser910 and Ser935 phosphorylation of both wild-type LRRK2 and G2019S mutant at a concentration of 0.1-0.3μM in cells and in mouse spleen and kidney, but not in brain, following oral doses of 10mg/kg.
CiteXplore: 22335897